Axellia acquires OTC maker

COPENHAGEN Axellia Pharmaceuticals on Tuesday announced its acquisition of the Phoenix Global Supply Group, based in White Plains, N.Y., to supply over-the-counter topical anti-infectives to the U.S. and Canadian markets.

“An important part of our strategy is to expand our offering to include finished products in targeted dosage forms and geographic markets,” said Axellia CEO Carl-Ake Carlsson, “while continuing to develop our core active pharmaceutical ingredients business.”

Phoenix's initial product launches in North America are expected to include private-label offerings around bacitracin and polymyxin B sulfate, two of the major ingredients found in topical anti-infective first aid products.

“The Phoenix team is delighted to welcome Axellia as its majority owner. While there are many other manufacturers of over-the-counter antibiotic products, we believe that the U.S. and Canadian markets for these products continue to be attractive and provide a significant opportunity for Phoenix,” stated Walter Jenkins, Phoenix CEO.

Login or Register to post a comment.